First Trust Advisors LP Buys 33,165 Shares of Merck & Co., Inc. (NYSE:MRK)

First Trust Advisors LP increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,421,805 shares of the company’s stock after buying an additional 33,165 shares during the period. First Trust Advisors LP owned 0.06% of Merck & Co., Inc. worth $119,688,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Merck & Co., Inc. by 0.8% during the 2nd quarter. Vanguard Group Inc. now owns 209,505,775 shares of the company’s stock worth $17,567,058,000 after acquiring an additional 1,694,360 shares during the period. BlackRock Inc. lifted its stake in shares of Merck & Co., Inc. by 2.3% in the second quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock valued at $16,087,745,000 after buying an additional 4,397,580 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Merck & Co., Inc. by 7.8% in the second quarter. Janus Henderson Group PLC now owns 24,839,949 shares of the company’s stock valued at $2,082,840,000 after buying an additional 1,790,405 shares in the last quarter. Nuveen Asset Management LLC lifted its stake in shares of Merck & Co., Inc. by 6,517.4% in the second quarter. Nuveen Asset Management LLC now owns 24,307,332 shares of the company’s stock valued at $2,038,169,000 after buying an additional 23,940,007 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Merck & Co., Inc. by 18.4% in the second quarter. Invesco Ltd. now owns 18,309,138 shares of the company’s stock valued at $1,535,222,000 after buying an additional 2,843,458 shares in the last quarter. 74.95% of the stock is owned by institutional investors and hedge funds.

NYSE MRK traded up $0.71 during trading hours on Friday, reaching $83.59. 6,348,296 shares of the company were exchanged, compared to its average volume of 10,105,755. Merck & Co., Inc. has a 1 year low of $70.89 and a 1 year high of $87.35. The business’s 50 day simple moving average is $84.03 and its 200-day simple moving average is $82.71. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $212.31 billion, a P/E ratio of 19.26, a P/E/G ratio of 1.80 and a beta of 0.54.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.27. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 47.94%. The business had revenue of $12.40 billion during the quarter, compared to the consensus estimate of $11.59 billion. During the same quarter last year, the company posted $1.19 earnings per share. The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

A number of research analysts have weighed in on the stock. Svb Leerink initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, August 16th. They issued an “outperform” rating and a $103.00 price objective on the stock. Bank of America initiated coverage on shares of Merck & Co., Inc. in a report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 target price for the company. Mizuho increased their target price on shares of Merck & Co., Inc. from $97.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Societe Generale set a $105.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. set a $96.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and a consensus price target of $95.13.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: Risk Tolerance and Your Investment Decisions

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply